U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07873827) titled 'KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies' on Oct. 08.
Brief Summary: This study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and activity of MEN2312 in participants with hematological malignancies.
Study Start Date: Oct. 30
Study Type: INTERVENTIONAL
Condition:
Hematological Malignancy
Intervention:
DRUG: MEN2312
Oral tablets
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Stemline Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....